Payment overview · 2025
General Payments
$897.18
39 reported records · 20 companies
Healthcare provider profile · identity verified
Ali Alsaadi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FARMINGTON HILLS, MI · NPI 1912941477
Verified facts
What the public records show
CMS Open Payments records show Ali Alsaadi, M.D. received $897.18 in general payments during 2025 across 39 reported records.
Medtronic, Inc. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 572 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$140.62 | 15.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $91.95 | 10.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.56 | 9.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.39 | 7.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.41 | 7.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $55.44 | 6.2% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $50.52 | 5.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.24 | 4.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.52 | 4.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $35.60 | 4.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.81 | 3.8% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $23.11 | 2.6% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $22.48 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.47 | 2.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.60 | 2.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.32 | 2.3% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $19.68 | 2.2% | 1 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.78 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.20 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.48 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $894.86 | 38 |
| Travel and Lodging | $2.32 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARDIOBLATE GEMINI Normalized: cardioblate gemini |
Device | Medtronic, Inc. | $118.30 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $99.68 | 4 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $73.98 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $69.39 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.11 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $50.52 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.08 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.08 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $41.48 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.52 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $35.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.71 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| INPEN SMART INSULIN DELIVERY SYSTEM Normalized: inpen smart insulin delivery system |
Device | Medtronic, Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| RALDESY Normalized: raldesy |
Drug | Validus Pharmaceuticals LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
572 | 116 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
59 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1377 | 313 |
| Amlodipine Besylate | Amlodipine Besylate | 999 | 228 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 588 | 150 |
| Hydralazine Hcl | Hydralazine Hcl | 587 | 127 |
| Eliquis | Apixaban | 572 | 116 |
| Furosemide | Furosemide | 546 | 142 |
| Losartan Potassium | Losartan Potassium | 514 | 129 |
| Metoprolol Tartrate | Metoprolol Tartrate | 481 | 113 |
| Clopidogrel | Clopidogrel Bisulfate | 467 | 98 |
| Carvedilol | Carvedilol | 466 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 438 | 110 |
| Gabapentin | Gabapentin | 405 | 105 |
| Mirtazapine | Mirtazapine | 393 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 73 |
| Levetiracetam | Levetiracetam | 357 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 110 |
| Potassium Chloride | Potassium Chloride | 328 | 53 |
| Tramadol Hcl | Tramadol Hcl | 267 | 79 |
| Lisinopril | Lisinopril | 262 | 65 |
| Sertraline Hcl | Sertraline Hcl | 245 | 43 |
| Trazodone Hcl | Trazodone Hcl | 231 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 91 |
| Omeprazole | Omeprazole | 223 | 93 |
| Donepezil Hcl | Donepezil Hcl | 215 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 215 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 204 | 25 |
| Divalproex Sodium | Divalproex Sodium | 202 | 17 |
| Baclofen | Baclofen | 190 | 42 |
| Ondansetron Hcl | Ondansetron Hcl | 181 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 176 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 175 | 37 |
| Olanzapine | Olanzapine | 169 | 17 |
| Metformin Hcl | Metformin Hcl | 166 | 45 |
| Nifedipine Er | Nifedipine | 162 | 39 |
| Glimepiride | Glimepiride | 158 | 31 |
| Midodrine Hcl | Midodrine Hcl | 158 | 48 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 151 | 39 |
| Simvastatin | Simvastatin | 142 | 52 |
| Bumetanide | Bumetanide | 138 | 41 |
| Jardiance | Empagliflozin | 138 | 37 |
| Famotidine | Famotidine | 135 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 133 | 39 |
| Methocarbamol | Methocarbamol | 131 | 60 |
| Gemtesa | Vibegron | 130 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 129 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 128 | 35 |
| Humalog Kwikpen U-100 | Insulin Lispro | 115 | 36 |
| Spironolactone | Spironolactone | 114 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 21 |
| Albuterol Sulfate | Albuterol Sulfate | 109 | 29 |
| Januvia | Sitagliptin Phosphate | 108 | suppressed |
| Clonazepam | Clonazepam | 107 | 18 |
| Farxiga | Dapagliflozin Propanediol | 106 | 21 |
| Buspirone Hcl | Buspirone Hcl | 101 | 17 |
| Labetalol Hcl | Labetalol Hcl | 99 | 24 |
| Latanoprost | Latanoprost | 94 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 11 |
| Heparin Sodium | Heparin Sodium,porcine | 86 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 25 |
| Alprazolam | Alprazolam | 83 | 22 |
| Allopurinol | Allopurinol | 80 | 36 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 80 | 31 |
| Xarelto | Rivaroxaban | 80 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 78 | 23 |
| Entresto | Sacubitril/Valsartan | 72 | 19 |
| Risperidone | Risperidone | 72 | 14 |
| Lactulose | Lactulose | 71 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 67 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 66 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 66 | 21 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 66 | suppressed |
| Atenolol | Atenolol | 65 | suppressed |
| Valsartan | Valsartan | 64 | 17 |
| Meloxicam | Meloxicam | 63 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 23 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 62 | suppressed |
| Ozempic | Semaglutide | 62 | suppressed |
| Budesonide | Budesonide | 61 | 11 |
| Cephalexin | Cephalexin | 61 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 27 |
| Benztropine Mesylate | Benztropine Mesylate | 60 | suppressed |
| Prednisone | Prednisone | 60 | 38 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 59 | 23 |
| Clonidine Hcl | Clonidine Hcl | 58 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 14 |
| Colchicine | Colchicine | 57 | 12 |
| Ibuprofen | Ibuprofen | 56 | 21 |
| Diltiazem Hcl | Diltiazem Hcl | 55 | 11 |
| Levofloxacin | Levofloxacin | 55 | 30 |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 54 | 15 |
| Digoxin | Digoxin | 53 | 12 |
| Glipizide | Glipizide | 53 | suppressed |
| Nitroglycerin | Nitroglycerin | 52 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | suppressed |
| Topiramate | Topiramate | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | 15 |
| Pregabalin | Pregabalin | 51 | 20 |
| Lansoprazole | Lansoprazole | 50 | suppressed |
| Novolog Flexpen | Insulin Aspart | 50 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 35 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 45 | 17 |
| Finasteride | Finasteride | 45 | 17 |
| Methylprednisolone | Methylprednisolone | 45 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 17 |
| Lorazepam | Lorazepam | 43 | 18 |
| Lubiprostone | Lubiprostone | 43 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 42 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 16 |
| Humalog | Insulin Lispro | 38 | 16 |
| Lidocaine | Lidocaine | 36 | 11 |
| Linzess | Linaclotide | 36 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 35 | 14 |
| Dorzolamide Hcl | Dorzolamide Hcl | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 25 |
| Calcium Acetate | Calcium Acetate | 34 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 24 |
| Enulose | Lactulose | 34 | 16 |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 32 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | 12 |
| Ezetimibe | Ezetimibe | 31 | 12 |
| Lacosamide | Lacosamide | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 30 | 12 |
| Methimazole | Methimazole | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | 11 |
| Hydrocortisone | Hydrocortisone | 28 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Haloperidol | Haloperidol | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Cholestyramine Light | Cholestyramine | 26 | 11 |
| Mirabegron Er | Mirabegron | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 25 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | 14 |
| Diazepam | Diazepam | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 12 |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Tivicay | Dolutegravir Sodium | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 21 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 16 |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | 11 |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | 12 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | 11 |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Scopolamine | Scopolamine | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Edurant | Rilpivirine Hcl | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $897.18 · 39 records | Medtronic, Inc. | AFREZZA, AREXVY, Arikayce, Auvelity, BEXSERO, BREZTRI, CARDIOBLATE GEMINI, Cologuard Collection Kit, INPEN SMART INSULIN DELIVERY SYSTEM, JASCAYD, KISUNLA, Leqembi, MOUNJARO, NUPLAZID, NURTEC ODT, OFEV, OTEZLA, PAXLOVID, RALDESY, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, TZIELD, XIFAXAN, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error